Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Beijing Double-Crane Buys Enshi Pharma for $13.7 Million

publication date: Dec 31, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Beijing Double-Crane Pharmaceutical will acquire Shenyang Enshi Pharmaceutical from Enshi Internation for 90 million RMB ($13.7 million). Enshi Pharma produced just 2.4 million RMB of revenue during the first four months of 2010, creating a loss of 3 million RMB. Double-Crane said the acquisition would boost production capacity of its cephalosporin antibiotics. More details....

Stock Symbol: (SHEX: 600062)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...